On March 2, 2022 Epizyme, (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering transformative therapies against novel epigenetic targets, reported its participation in two investor conferences in March (Press release, Epizyme, MAR 2, 2022, View Source [SID1234609404]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Cowen 42nd Annual Health Care Conference
Shefali Agarwal, Chief Medical Officer, will participate in the Cowen 42nd Annual Health Care Conference as part of the Targeted Oncology panel.
Tuesday, March 8, at 9:10am EST

Barclays Global Healthcare Conference
Grant Bogle, Chief Executive Officer, will participate in a fireside chat at the Barclays Global Healthcare Conference.
Tuesday, March 15, 2022, at 2:05pm EST

Live webcasts of the presentations will be available under the investor section of the Company’s website at www.epizyme.com, and will be archived for 60 days following the event.